Q2i, a Boston-based digital health company, announced on Tuesday it has received approval to move to phase two of its Opioid Addiction Recovery Support – Contingency Management software application, a project done in partnership with UMass Medical School in Worcester and UConn School of Medicine.
In the second phase OARS-CM will streamline connection to the emergency department and community-based providers for individuals with opioid abuse disorders.
Included in the program is a healthcare provider portal and a reward program for individuals sticking with a treatment plan.
Phase I of the clinical trial took place at Worcester’s UMass Medical School, with Dr. Edwin Boudreaux of UMass leading the research team.
